Glycoforms of MUC5AC and Endorepellin and Biomarkers for Mucinous Pancreatic Cysts
OwnerBrian Brummeler Haabinventor
Life of this patent
Estimating the term…
Abstract
The present invention relates to a method for diagnosing a subject with a malignant pancreatic cyst, the method comprising, obtaining a pancreatic cyst fluid sample from a pancreatic cyst lesion of the subject, detecting the level of MUC5AC, and endorepellin glycoforms present in the pancreatic cyst fluid sample, comparing the levels of MUC5AC and endorepellin glycoforms to a control pancreatic cyst sample level of MUC5AC and endorepellin glycoforms; and diagnosing the pancreatic cyst lesion as malignant if the levels of the MUC5AC and endorepellin glycoforms are differentially expressed compared to the levels of the MUC5AC and endorepellin glycans present in control pancreatic cyst samples.
Claims20
A method for diagnosing whether a pancreatic cystic lesion in a subject is malignant, the method comprising:
- a. obtaining a pancreatic cyst fluid sample from a pancreatic cystic lesion in the subject;
- b. detecting levels of glycoforms of MUC5AC and endorepellin in the sample;
- c. comparing the glycoform levels of MUC5AC and endorepellin in the sample to control levels of these glycoforms of MUC5AC and endorepellin in control pancreatic cyst samples;
- and
- d. diagnosing the pancreatic cystic lesion as malignant if the glycoform levels of the MUC5AC and endorepellin in the sample are differentially expressed as compared to the control levels of these glycoforms of MUC5AC and endorepellin.
A method for determining the malignant potential of a pancreatic cyst lesion in a subject having or suspected of having pancreatic cancer, comprising:
- a. obtaining a pancreatic cyst fluid sample from a pancreatic cyst lesion in the subject;
- b. measuring in the sample levels of MUC5AC glycoforms detected by wheat-germ agglutinin (MUC5AC-WGA) and by an antibody to blood group H (MUC5AC-BGH);
- c. measuring in the sample the level of an endorepellin glycoform using wheat-germ agglutinin (endorepellin-WGA);
- d. comparing the levels of MUC5AC-WGA, MUC5AC-BGH, and endorepellin-WGA glycoforms in the sample to a statistical threshold level for MUC5AC-WGA, MUC5AC-BGH, and endorepellin-WGA glycoforms obtained from a comparable control of non-malignant pancreatic cyst lesions;
- and
- e. determining that the pancreatic cyst lesion of the subject is a malignant pancreatic cyst if two of the three levels of MUC5AC-WGA, MUC5AC-BGH, and endorepellin-WGA glycoforms are higher in the pancreatic cyst fluid sample than the two of the three levels of MUC5AC-WGA, MUC5AC-BGH and endorepellin-WGA glycoforms in the comparable control of non-malignant pancreatic cyst lesions.
A kit comprising:
- a. a substrate for depositing a discrete sample specimen;
- b. at least one binding reagent, the at least one binding reagent operable to bind specifically to at least two glycoforms selected from MUC5AC glycoforms and an endorepellin glycoform present in the discrete sample specimen;
- and
- c. a detection reagent operable to identify a complex formed between the at least one binding reagent and the at least two glycoforms.
Dependencies are inferred from the claim text.